{
  "docId": "019dd923-622c-750b-8b9a-101b5bfde4b8",
  "docSlug": "a70fecd99534",
  "documentTitle": "Berkeley Lights (BLI)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-09-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 40,
  "pageCount": 158,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "executive_summary",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses bold text to emphasize critical negative sentiment from interviewees.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-101b5bfde4b8/40",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8#slide-40",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "GINGKO BIOWORKS announced a purported “$150MM deal” with BLI in 2019. We spoked with two Gingko executives, both of whom hesitated and expressed concerns when we asked if they’d ever personally invest in BLI",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2041-7259-a876-03fe5e57850a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Executive #1 said it’s too early to say whether the tool can compete against other screening technologies – a troubling statement given the deal was inked two years ago; not obvious what to use the instrument for and still trying to figure it out; executive doesn’t “want to be unnecessarily pessimistic” but was nonetheless highly circumspect about the partnership.\nStill just “a concept on paper” that hasn’t been operationalized; unclear if machine is built for the right set of applications; “hard to know” how it compares to other ways of screening; “just so early.”\nChallenged the machine’s purported value proposition: doesn’t speed up overall workflows for pharma/biotech customers; throughput is a limitation; instrument is difficult to use and not usable by typical pharma/biotech companies nor as appealing to regular Gingko staff either\nExecutive #2 stated they have 2 BLI FTE’s on site to operate the machines and that their experience is not applicable to typical biotech/pharma customers for antibody discovery or cell line development.\nStated that they have extensively hacked and re-engineered BLI’s machine to get it to work for certain purposes: re-designed BLI’s chips, optics, and other components; machine they’re using is not typical and has a different architecture.\nGingko hires from Amgen, Genentech indicated “consistency issues” with the instrument.\nDemurred on personally investing in BLI; wants to see “success”; space is crowded; other companies have “been smarter” in designing their machines; doesn’t see BLI “taking off” in the antibody discovery space.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "444e4e4f-adf1-445d-915b-ed85ccb52adf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "GINGKO BIOWORKS announced a purported “$150MM deal” with BLI in 2019. We spoke with two Gingko executives, both of whom hesitated and expressed concerns when we asked if they’d ever personally invest in BLI; both were surprisingly cautious about the collaboration and wouldn’t confirm if they actually paid for their 3 machines; “jury is still out” 24 months later, still just “a concept on paper”; challenged the tool’s value proposition and hesitated to recommend it; not usable by typical biotech/pharma companies; have had to hack the machine and develop new chips to make it usable; still 50/50 whether experiments work or fail; suggested the deal will never approach the headline “deal size.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c4347e6-72cb-4c86-a3ba-df4b52a66dea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“jury is still out” — Gingko Executive; “a concept on paper” — Gingko Executive; “hard to know” — Gingko Executive; “consistency issues” — Gingko Executive; “been smarter” — Gingko Executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2041-7259-a876-06dff4dc795a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83bdf59a-569e-438c-8ada-7915c12242f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "2) Summary of findings from customer interviews",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e1a725f-2bff-4ba8-a52d-65c0de28777f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 75,
      "from": 17,
      "beatId": "dbc4e03f-819a-4342-92d6-d159c538f28f",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Exposure of Contradictions",
      "beatSlug": null,
      "evidence": "The document exposes contradictions in Berkeley Lights' claims and actions, highlighting the company's struggles and poor market traction.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}